Navigation Links
Malaria Vaccine Developer, Sanaria Inc., Receives 2009 Vaccine Industry Excellence Award for Best Early-Stage Vaccine Biotech
Date:6/2/2009

ROCKVILLE, Md., June 2 /PRNewswire/ -- The award was announced on April 21, 2009 at the World Vaccine Congress Washington conference. The Vaccine Industry Excellence awards recognize the accomplishments and contributions of companies and individuals working in the vaccine industry. Sanaria was named Best Early-Stage Vaccine Biotech from a group of nine companies shortlisted for the award. Other awardees included GlaxoSmithKline Biologicals for Best Vaccine R&D Pipeline and Merck for Best Prophylactic Vaccine.

"This award caps a remarkable period of rapid progress and success in translating Sanaria's whole-organism, sporozoite malaria vaccine candidate from development through cGMP manufacturing and the initiation of clinical trials. It recognizes the remarkable achievements and dedication of the entire Sanaria team and our collaborators," states Stephen L. Hoffman, Sanaria's founder and CEO.

Sanaria's candidate malaria vaccine is composed of live, attenuated parasites. This unique formulation, having satisfied rigorous FDA scrutiny for safety, sterility, purity, potency, and reproducibility of manufacturing, is now undergoing clinical testing in volunteers for safety and efficacy.

About Sanaria Inc. The company's primary mission is to develop and commercialize a malaria sporozoite vaccine against Plasmodium falciparum, the parasite responsible for more than 95 percent of malaria-associated severe illness and death worldwide, and the malaria parasite for which there is the most significant drug resistance. Sanaria's corporate headquarters, administrative, research, development, and manufacturing operations are located in Rockville, Maryland. The company's Web site is

http://www.sanaria.com.

Except for historical information, this news release contains certain forward-looking statements that involve known and unknown risk and uncertainties, which may cause actual results to differ materially from any future results, performance or achievements expressed or implied by the statements made. Such statements include expectations for the effectiveness of a vaccine and its usefulness. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, without limitation, the Company's ability to raise sufficient funds, the regulatory approval process, dependence on third-parties, clinical trials results, and the ability to commercialize the vaccine.

For further information contact: Media- Adam Richman 301.770.3222, Investors- Robert Thompson 240.403.2750


'/>"/>
SOURCE Sanaria Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Progress Against Malaria and Other Infectious Diseases Among Highlights at Annual Vaccine Conference
2. Phase 1 Trial of Whole-Parasite Malaria Vaccine to Begin
3. USAID Provides Malaria Assistance to Zimbabwe
4. Two New Studies in the New England Journal of Medicine Show Malaria Vaccine Candidate Advancing in Africa
5. Malaria Vaccine Developer Sanaria Inc. Receives the Technology Council of Marylands Emerging Company of the Year Award
6. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
9. Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine
10. Novel Vaccine Approach Offers Hope in Fight Against HIV
11. Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
(Date:6/23/2016)... , June 23, 2016 Research ... MEMS Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data ... analysis. Assessment of major trends with potential impact on the ... analysis of market segmentation which comprises of sub markets, regional ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, ... a Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, ... winners, announced today online at www.diabetesscholars.org by ... 1 diabetes stand in the way of academic and ... the Foundation,s scholarship program since 2012, and continues to ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever ... Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation ... as home to some of the world’s leading providers of cereal and other breakfast ...
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
Breaking Medicine News(10 mins):